1.Aguiar-Bujanda D，Blanco-Sánchez MJ，Hernández-Sosa M，et al. Late-onset neutropenia after rituximabcontaining therapy for non-Hodgkin Lymphoma［J］. Clin Lymphoma Myeloma Leuk，2015，635：2152-2650.

2.Chiara Cattaneo，Spedini P，Casari S，et al. Delayed-onset peripheral blood cytopenia after rituximab：frequency and risk factor assessment in a consecutive series of 77 treatments［J］. Leuk Lymphoma，2006，47：1013-1017.

3.Davis T，Grillo-Lopez A，White C，et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma：safety and efficacy of re-treatment ［J］. J Clin Oncol，2000，18：3135-3143.

4.Chaiwatanatorn K，Lee N，Grigg A，et al. Delayed-onset neutropenia associated with rituximab therapy［J］. Br J Haematol，2003；121：913-918.

5.Liu JH，Wei S，Lamy T，et al. Chronic neutropenia mediated by fas ligand［J］. Blood，2000，95：3219-3222.

6.Dunleavy K，Hakim F，Kim HK，et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis［J］. Blood，2005，106：795-802.

7.Daniel Tesfa，Jan Palmblad. Late-onset neutropenia following rituximab therapy：incidence，clinical features and possible mechanisms［J］. Expert Rev. Hematol，2011，4（6）：619-625.